Written question asked by Tim Loughton (Conservative) on Tuesday, 8 June 2004, in the House of Commons. It was due for an answer on Tuesday, 22 June 2004. It was answered by Baroness Winterton of Doncaster (Labour) on Tuesday, 22 June 2004 on behalf of the Department of Health.

Dept of Health

Question: To ask the Secretary of State for Health, whether the review of selective serotonin reuptake inhibitor and related antidepressants includes investigation of whether such drugs may induce violent and dangerous behaviour in some users; whether the drugs (a) mirtazapine and (b) bupropion were included in the review of selective serotonin reuptake inhibitor antidepressants and related drugs; and if he will conduct an assessment of whether each drug carries a risk of inducing suicidal behaviour. - Inc ref to 22 June 2004, 422 c1336-7W.

Answer: Mr. Burstow: To ask the Secretary of State for Health (1) whether the review of selective serotonin reuptake inhibitors and related anti-depressants includes an assessment of possible risks that such drugs may induce violent and dangerous behaviour in some users; [178441] (2) whether mirtazapine and bupropion are included in the review of selective serotonin reuptake inhibitors and related drugs; [178469] (3) what advice he has received on whether mirtazapine and buproprion carry a risk of inducing suicidal behaviour. [178567] Tim Loughton: To ask the Secretary of State for Health (1) whether the review of selective serotonin reuptake inhibitor and related anti-depressants includes investigation of whether such drugs may induce violent and dangerous behaviour in some users; [178337] (2) whether the drugs (a) mirtazapine and (b) bupropion were included in the review of selective serotonin reuptake inhibitor anti-depressants and related drugs; and if he will conduct an assessment of whether each drug carries a risk of inducing suicidal behaviour. [178338] Ms Rosie Winterton: I refer the hon. Members to the reply I gave to my hon. Friend the Member for Newport, West (Paul Flynn) today.

Secondary information

Type: Written question
Reference: 422 c1337W; 178337;178338
Session: 2003-04
Subjects: Anti-social behaviour Depressive illnesses Drugs Prescription drugs Safety Research Side effects Suicide Antidepressants Bupropion Mirtazapine
Link: View this Written question on www.publications.parliament.uk